Interleukin-6 production by rat hepatocellular carcinoma cells is associated with metastatic potential but not with tumorigenicity

Archives of Surgery

Volumn 131, Issue 4, 1996, Pages 360-365

  Reichner, Jonathan S ^a,b   Mulligan, James A ^a   Palla, Mark E ^a   Hixson, Douglas C ^a   Albina, Jorge E ^a   Bland, Kirby I ^a  

^a BROWN UNIVERSITY   (United States)

^b RHODE ISLAND HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 6;

ANIMAL CELL; ARTICLE; CARCINOGENICITY; CORRELATION FUNCTION; LIVER CELL CARCINOMA; METASTASIS; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; RAT; STATISTICAL ANALYSIS;

EID: 0029988916     PISSN: 00040010     EISSN: None     Source Type: Journal    
DOI: 10.1001/archsurg.1996.01430160018002     Document Type: Article

References (24)

1. Fidler IJ Critical factors in the biology of human cancer metastasis twenty-eighth G H. A. Clowes Memorial Lecture. Cancer Res 1990;50 6130-6138.
2. Muschel R, Liotta LA. Role of oncogenes in metastases Carcinogenesis. 1988; 9:705-710
3. Lu C, Kerbel RS. Cytokines, growth factors and the loss of negative growth controls in ths progression of human cutaneous malignant melanoma. Curr Opin Oncol 1994;6:212-220
4. Kishimoto T. The biology of interleukin-6. Blood. 1989,74:1-10.
5. Mateo RB, Reichner JS, Albina JE. Interleukin-6 activity in wounds Am J Physiol. 1994;266 R1840-R1844
6. Tabibzadeh SS, Poubouridis D, May LT, Sehgal PB. Interleukin-6 immunore-activtty in human tumors Am J Pathol. 1989;135:427-433.
7. Akira S, Kishimoto T. IL-6 and NF-IL6 in acute-phase response and viral infection. Immunol Rev 1992,127 25-50.
8. Hixson DC. McEntire KD, Obrink B Alterations in the expression of a hepatocyte cell adhesion molecule by transplantable rat hepatocellular carcinomas Cancer Res 1985;45.3742-3749
9. Freshney RI. Culture of Animal Cells: A Manual of Basic Technique. New York, NY Alan R Liss Inc: 1983.
10. Coligan JE, Kruisbeek AM, Margulies DH, Shevach EM, Strober W, eds. Current Protocols in Immunology. New York, NY: John Wiley & Sons Inc: 1995; 1:chap2 5,10.
11. Nicolson GL. Tumor microenvironment: paracrine and autocrine growth mechanisms and metastasis to specific sites In. Meyer JL, ed The Lymphatic System and Cancer Basel, Switzerland S Karger AG, 1994:11-24.
12. Herrlich P. Zoller M, Pals ST, Ponta H CD44 splice variants: metastases meet lymphocytes Immunol Today. 1993;14 395-399
13. Yoshiura K, Kanai Y, Ochiai A, et al. Silencing of the E-cadherin invasion-suppressor gene by CpG methylation in human carcinomas. Proc Natl Acad Sci U S A. 1995;92 7416-7419.
14. Fung CY, Fisher DE. P53: from molecular mechanisms to prognosis in cancer J Clin Oncol. 1995;13:808-811.
15. Filmus J, Kerbel RS. Development of resistance mechanisms to the growth-inhibitory effects of transforming growth factor-b during tumor progression Curr Opin Oncol. 1993;5:123-129
16. Serve H. Steinhauser G, Oberberg D, et al. Studies on the interaction between interleukin 6 and human malignant nonhematopoietic cell lines. Cancer Res 1991;51:3862-3866.
17. Zhang XG, Klein B, Bataille R. Interteukin-6 is a potent myeloma-cell growth factor in patients with aggressive multiple myeloma. Blood. 1989;74:11-13.
18. Schwarz LC, Gingras M-C, Goldberg G, Greenberg AH, Wright JA Loss of growth factor dependence and conversion of transforming growth factor-B1 inhibition to stimulation in metastatic H-ras-transformed murine fibroblasts. Cancer Res. 1988 48 6999-7003
19. Lu C, Vickers MF, Kerbel RS. Interleukin 6. a fibroblast-derived growth inhibitor of human melanoma cells from early but not advanced stages of tumor progression Proc Natl Acad Sci USA. 1992;89:9215-9219.
20. Kerbel RS. Expression of multi-cytokine resistance and multi-growth factor independence in advanced stage metastatic cancer malignant melamona as a paradigm. Am J Pathol. 1992;141:519-524.
21. Lu C, Kerbel RS. Interleukin-6 undergoes transition from paracrine growth inhibitor to autocrine stimulator during human melanoma progression. J Cell Biol. 1993;120.1281-1288.
22. Sun WH, Kreisle RA, Phillips AW, Ershler WB, In vivo and in vitro characteristics of interleukin 6-transfected B16 melanoma cells. Cancer Res. 1992;52: 5412-5415.
23. Mullen CA, Coale MM, Levy AT, et al. Fibrosarcoma cells transduced with the IL-6 gene exhibit reduced tumorigenicity, increased immunogenicity, and decreased metastatic potential. Cancer Res. 1992;52:6020-6024.
24. Mule JJ, Custer MC, Travis WD, Rosenberg SA. Cellular mechanisms of the antifumor activity of recombinant IL-6 in mice. J Immunol 1992;148:2622-2629.